Top

Published in:

01-02-2019 | Research Article

CalliSpheres® drug-eluting beads (DEB) transarterial chemoembolization (TACE) is equally efficient and safe in liver cancer patients with different times of previous conventional TACE treatments: a result from CTILC study

Authors: X. Zhang, J. Zhou, D.-D. Zhu, J. Huang, J.-H. Sun, T.-F. Li, C.-S. Shi, Z.-C. Sun, Q.-M. Hou, Z.-Y. Peng, W.-Q. Yu, J.-S. Ji, W.-J. Gu, G.-H. Zhou, X.-X Xie, X.-H. Guo, G.-H. Cao, Z.-H. Yu, H.-H. Xu, J. Fang, S.-H. Ying, W.-H. Hu, W.-B. Ji, J. Han, X. Wu, J.-P. Zheng, J. Luo, Y.-T. Chen, T.-Y. Hu, L. Li, H.-J. Hu, H.-J. Du, G.-L. Shao

Published in: Clinical and Translational Oncology | Issue 2/2019

Abstract

Purpose

To assess the efficacy and safety of drug-eluting beads transarterial chemoembolization (DEB-TACE) in liver cancer patients with different times of previous conventional transarterial chemoembolization (cTACE) treatments.

Methods

367 liver cancer patients about to receive DEB-TACE treatment were enrolled in this prospective cohort study. All patients were divided into no previous cTACE group (NPC group), 1–2 times previous cTACE group (PC group) and triple or above previous cTACE group (TPC group) according to the times of previous cTACE treatments.

Results

There was no difference in complete response (CR) (P = 0.671) and objective response rate (ORR) (P = 0.062) among three groups. Additionally, no difference in overall survival (OS) among groups (P = 0.899) was found. As to liver function, most liver function indexes were deteriorative at 1 week after DEB-TACE operation, but returned to baseline at 1–3 months after DEB-TACE operation in all three groups, while percentage of abnormal total bile acid (TBA) patients was higher in TPC group than NPC and PC groups at 1–3 month post-DEB-TACE (P = 0.018). As for safety profiles, the incidence of pain during DEB-TACE operation was lower in TPC group compared to NPC and PC groups (P = 0.005), while no difference of other adverse events was found during and 1 month post-DEB-TACE treatment among three groups.

Conclusion

DEB-TACE treatment was equally efficient and tolerated in liver cancer patients with different times of previous cTACE treatments.

Available only for authorised users

Recio-Boiles A, Babiker HM. Cancer, Liver. StatPearls. Treasure Island (FL)2017.

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. https://doi.org/10.3322/caac.21262.CrossRefPubMed

Chen P, Yuan P, Chen B, Sun J, Shen H, Qian Y. Evaluation of drug-eluting beads versus conventional transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2017;41(1):75–85. https://doi.org/10.1016/j.clinre.2016.05.013.CrossRefPubMed

European Association For The Study Of The. L, European Organisation For R, Treatment Of C. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908–43. https://doi.org/10.1016/j.jhep.2011.12.001.CrossRef

Bruix J, Sherman M. American Association for the Study of Liver D. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020–2. https://doi.org/10.1002/hep.24199.CrossRefPubMed

Ludwig JM, Zhang D, Xing M, Kim HS. Meta-analysis: adjusted indirect comparison of drug-eluting bead transarterial chemoembolization versus 90Y-radioembolization for hepatocellular carcinoma. Eur Radiol. 2017;27(5):2031–41. https://doi.org/10.1007/s00330-016-4548-3.CrossRefPubMed

Ni JY, Xu LF, Wang WD, Sun HL, Chen YT. Conventional transarterial chemoembolization vs microsphere embolization in hepatocellular carcinoma: a meta-analysis. World J Gastroenterol. 2014;20(45):17206–17. https://doi.org/10.3748/wjg.v20.i45.17206.CrossRefPubMedPubMedCentral

Xie ZB, Wang XB, Peng YC, Zhu SL, Ma L, Xiang BD, et al. Systematic review comparing the safety and efficacy of conventional and drug-eluting bead transarterial chemoembolization for inoperable hepatocellular carcinoma. Hepatol Res. 2015;45(2):190–200. https://doi.org/10.1111/hepr.12450.CrossRefPubMed

Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52–60. https://doi.org/10.1055/s-0030-1247132.CrossRefPubMed

10.

Terzi E, Golfieri R, Piscaglia F, Galassi M, Dazzi A, Leoni S, et al. Response rate and clinical outcome of HCC after first and repeated cTACE performed “on demand”. J Hepatol. 2012;57(6):1258–67. https://doi.org/10.1016/j.jhep.2012.07.025.CrossRefPubMed

11.

Sangro B, D’Avola D, Inarrairaegui M, Prieto J. Transarterial therapies for hepatocellular carcinoma. Expert Opin Pharmacother. 2011;12(7):1057–73. https://doi.org/10.1517/14656566.2011.545346.CrossRefPubMed

12.

Kudo M, Matsui O, Izumi N, Kadoya M, Okusaka T, Miyayama S, et al. Transarterial chemoembolization failure/refractoriness: JSH-LCSGJ criteria 2014 update. Oncology. 2014;87(Suppl 1):22–31. https://doi.org/10.1159/000368142.CrossRefPubMed

13.

Facciorusso A, Di Maso M, Muscatiello N. Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma: a meta-analysis. Dig Liver Dis. 2016;48(6):571–7. https://doi.org/10.1016/j.dld.2016.02.005.CrossRefPubMed

14.

Song MJ, Chun HJ, Song DS, Kim HY, Yoo SH, Park CH, et al. Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J Hepatol. 2012;57(6):1244–50. https://doi.org/10.1016/j.jhep.2012.07.017.CrossRefPubMed

15.

Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol. 2010;33(1):41–52. https://doi.org/10.1007/s00270-009-9711-7.CrossRefPubMed

16.

Song DS, Choi JY, Yoo SH, Kim HY, Song MJ, Bae SH, et al. DC bead transarterial chemoembolization is effective in hepatocellular carcinoma refractory to conventional transarteral chemoembolization: a pilot study. Gut Liver. 2013;7(1):89–95. https://doi.org/10.5009/gnl.2013.7.1.89.CrossRefPubMedPubMedCentral

17.

Huang K, Zhou Q, Wang R, Cheng D, Ma Y. Doxorubicin-eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma. J Gastroenterol Hepatol. 2014;29(5):920–5. https://doi.org/10.1111/jgh.12439.CrossRefPubMed

18.

Zou JH, Zhang L, Ren ZG, Ye SL. Efficacy and safety of cTACE versus DEB-TACE in patients with hepatocellular carcinoma: a meta-analysis. J Dig Dis. 2016;17(8):510–7. https://doi.org/10.1111/1751-2980.12380.CrossRefPubMed

19.

Jang JH, Lee JW, Hong JT, Jin YJ. Transarterial chemoembolization for hepatocellular carcinoma: an evidence-based review of its place in therapy. J Hepatocell Carcinoma. 2015;2:123–9. https://doi.org/10.2147/JHC.S44380.CrossRefPubMedPubMedCentral

20.

Crispe IN. The liver as a lymphoid organ. Annu Rev Immunol. 2009;27:147–63. https://doi.org/10.1146/annurev.immunol.021908.132629.CrossRefPubMed

Title: CalliSpheres® drug-eluting beads (DEB) transarterial chemoembolization (TACE) is equally efficient and safe in liver cancer patients with different times of previous conventional TACE treatments: a result from CTILC study
Authors: X. Zhang
J. Zhou
D.-D. Zhu
J. Huang
J.-H. Sun
T.-F. Li
C.-S. Shi
Z.-C. Sun
Q.-M. Hou
Z.-Y. Peng
W.-Q. Yu
J.-S. Ji
W.-J. Gu
G.-H. Zhou
X.-X Xie
X.-H. Guo
G.-H. Cao
Z.-H. Yu
H.-H. Xu
J. Fang
S.-H. Ying
W.-H. Hu
W.-B. Ji
J. Han
X. Wu
J.-P. Zheng
J. Luo
Y.-T. Chen
T.-Y. Hu
L. Li
H.-J. Hu
H.-J. Du
G.-L. Shao
Publication date: 01-02-2019
Publisher: Springer International Publishing
Published in: Clinical and Translational Oncology / Issue 2/2019
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-018-1902-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2019

Prognostic analysis of stage III gastric cancer after curative surgery according to the newest TNM classification

Outcomes of early-stage breast cancer patients treated with sequential anthracyclines–taxanes in relationship to relative dosing intensity: a secondary analysis of a randomized controlled trial

The value of radical radiotherapy in the primary tumor of newly diagnosed oligo-metastatic nasopharyngeal carcinoma patients

Differential molecular markers of primary lung tumors and metastatic sites indicate different possible treatment selections in patients with metastatic lung adenocarcinoma

The microRNA signatures: aberrantly expressed miRNAs in prostate cancer

Tumor-derived exosomes in cancer metastasis risk diagnosis and metastasis therapy

Keynote webinar | Spotlight on antibody–drug conjugates in cancer